Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

At the J.P. Morgan Healthcare Conference, Moderna (MRNA) announced several financial updates on its business and updates on its pipeline progress.Financial UpdatesFor 2023Moderna reported unaudited/preliminary product sales of nearly $6.7 billion for 2023, which were generated in its entirety from the sales of its mRNA-based COVID-19 vaccine. This figure was in line with the company’s previously reported guidance outlook, wherein it expected full-year vaccine sales to be at least $6 billion.The reported pre ...